Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02169895
Other study ID # BIA-91067-107
Secondary ID
Status Completed
Phase Phase 1
First received January 20, 2012
Last updated January 8, 2015
Start date September 2008
Est. completion date November 2008

Study information

Verified date January 2015
Source Bial - Portela C S.A.
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of immediate-release levodopa/benserazide 100/25 mg (Prolopa® 100-25)


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date November 2008
Est. primary completion date November 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 25 Years to 45 Years
Eligibility Inclusion Criteria:

1. Availability for the entire study period and willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the volunteer prior to participation in the study.

2. Male volunteers.

3. Volunteers of at least 25 years of age but not older than 45 years.

4. Volunteers with body mass index (BMI) greater than or equal to 19 and below 30 kg/m2.

5. Volunteers who are non- or ex-smokers. An ex-smoker is defined as someone who completely stopped smoking for at least 12 months before day 1 of this study.

6. Volunteers who are healthy as determined by pre-study (at screening) medical history, physical examination, vital signs, complete neurological examination and 12-lead ECG.

7. Volunteers who have clinical laboratory test results judged clinically acceptable (within the laboratory's stated normal range; if not within this range, they must be without any clinical significance) at screening and admission to first treatment period.

8. Volunteers who have negative tests for hepatitis B surface antigen (HBsAg), anti-hepatitis C antibodies (HCV Ab), and Human immunodeficiency viruses -1 and -2 antibodies (HIV-1 and HIV-2 Ab) at screening.

9. Volunteers who have negative screen of ethyl alcohol and drugs of abuse at screening.

10. Due to unknown risks and potential harm to the unborn fetus, sexually active men must agree to use a medically acceptable form of contraception throughout the study.

Exclusion Criteria:

1. Volunteers who do not conform to the above inclusion criteria, or in case of

2. Volunteers who have a clinically relevant surgical history.

3. Volunteers who have a clinically relevant family history.

4. Volunteers who have a history of relevant atopy.

5. Volunteers who have a significant infection or known inflammatory process at screening or first admission.

6. Volunteers who have acute gastrointestinal symptoms at the time of screening or first admission (e.g., nausea, vomiting, diarrhoea, heartburn).

7. Volunteers who are vegetarians, vegans or have medical dietary restrictions.

8. Volunteers who cannot communicate reliably with the investigator.

9. Volunteers who are unlikely to co-operate with the requirements of the study.

10. Significant history of hypersensitivity to BIA 9-1067, tolcapone, entacapone, levodopa, benserazide or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs.

11. Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects.

12. History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability.

13. Presence or history of significant cardiovascular, pulmonary, hematologic, neurologic, psychiatric, lymphatic, musculoskeletal, genitourinary, endocrine, immunologic, dermatologic or connective tissue disease.

14. Suicidal tendency, history of or disposition to seizures, state of confusion, clinically relevant psychiatric diseases.

15. Presence of significant heart disease or disorder according to ECG.

16. Presence of suspicious undiagnosed skin lesions or a history of melanoma.

17. Previous history of Neuroleptic Malignant Syndrome (NMS) and/or nontraumatic rhabdomyolysis.

18. Presence or history of significant glaucoma.

19. Use of prescription medications including MAO inhibitors within 28 days before day 1 of the study.

20. Use of over-the-counter (OTC) products within 7 days before day 1 of the study.

21. Maintenance therapy with any drug, or significant history of drug dependency (drug abuse) or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic).

22. Any clinically significant illness in the previous 28 days before day 1 of this study.

23. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin and rifampin), in the previous 28 days before day 1 of this study.

24. Volunteers who took an Investigational Product (in another clinical trial) or donated 50 mL or more of blood in the previous 28 days before day 1 of this study.

25. Poor motivation, intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with the protocol requirements or inability to cooperate adequately, inability to understand and to observe the instructions of the physician.

26. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study.

27. Positive urine screening of ethyl alcohol or drugs of abuse at admission to any treatment period.

28. Any history of tuberculosis and/or prophylaxis for tuberculosis.

29. Positive results to HIV, HBsAg or anti-HCV tests.

30. Participation in any previous clinical study with BIA 9-1067 within 84 days before day 1 of the study.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
BIA 9-1067

Placebo

Prolopa®
levodopa/benserazide 100/25 mg

Locations

Country Name City State
Canada Algorithme Pharma Inc Mount-Royal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Bial - Portela C S.A.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Observed Plasma Drug Concentration (Cmax) Cmax - Maximum observed plasma drug concentration of benserazide pre-dose, 0.5,1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 and 72 h post-dose No
Primary Tmax - Time of Occurrence of Cmax tmax - time of occurrence of Cmax of benserazide pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 and 72 h post-dose No
Primary AUC0-t - Area Under the Plasma Concentration-time Curve AUC0-t - area under the plasma concentration-time curve of benserazide. pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48 and 72 h post-dose. No
See also
  Status Clinical Trial Phase
Completed NCT02170376 - The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics Phase 1
Completed NCT02169479 - Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa Phase 1
Completed NCT02778594 - Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide Phase 1
Completed NCT02274766 - Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia Phase 3
Completed NCT02169453 - Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa Phase 1
Completed NCT04380142 - Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease Phase 3
Withdrawn NCT06118294 - Efficacy of Probiotics for Parkinson Disease (PD) N/A
Recruiting NCT05916157 - An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
Completed NCT03033498 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease Phase 1
Completed NCT02169427 - An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites Phase 1
Completed NCT02834507 - Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients Phase 2
Active, not recruiting NCT04379050 - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease Phase 3
Completed NCT02169440 - Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin Phase 1
Completed NCT02202551 - Open-Label Safety Study of ADS-5102 in PD Patients With LID Phase 3
Completed NCT01398748 - Intranasal Glutathione in Parkinson's Disease Phase 1
Recruiting NCT06107426 - Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
Completed NCT02169466 - Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide Phase 1
Recruiting NCT03732898 - Coordinated Reset Deep Brain Stimulation N/A
Completed NCT02799381 - A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER) Phase 3
Terminated NCT03829657 - Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure Phase 3